Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
New CE-marked algorithm for the Azurion platform delivers improved image quality with over 50% lower radiation dose compared to the lowest settings on ClarityIQ
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The programme has already drawn over 120 complex percutaneous coronary intervention (PCI) case submissions from across the country
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
This marks the fourth acquisition by Corona Remedies from multinational corporations
Subscribe To Our Newsletter & Stay Updated
